In Brief: Oncologic Drugs Advisory Committee
Executive Summary
Oncologic Drugs Advisory Committee: At its June 8-9 meeting, the committee will review Rhone-Poulenc Rorer's Taxotere (docetaxel) for patients with locally advanced or metastatic breast carcinoma in whom previous therapy has failed and NeXstar's liposomal daunorubicin DaunoXome on June 8 ("The Pink Sheet" April 17, T&G-1). The committee recommended against approval of Taxotere based on Phase II data Dec. 12 ("The Pink Sheet" Dec. 19, 1994, p. 7). On June 9, the committee will review U.S. Bioscience's Ethyol (amifostine injection) for the cumulative renal toxicity associated with cisplatin and the cumulative hematologic toxicity of cyclophosphamide and cisplatin. The committee found the drug needed further study in recommending against approval Dec. 12 at Ethyol's second advisory committee review ("The Pink Sheet" Dec. 19, 1994, p. 11)...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth